Five hundred consecutive patients underwent aortic valve replacement and coronary revascularization in the years from 1967 to 1981, with 29 (5.9%) in-hospital deaths. Current operative mortality (1978)(1979)(1980)(1981) is 3.4%. Univariate and multivariate analyses were used to identify determinants of early and late risk. Female sex, aortic insufficiency, and advanced age increased in-hospital mortality, whereas use of cardioplegia decreased it. At follow-up of 471 patients who survived hospitalization for 1 to 135 months (mean 41) after surgery, 96 late deaths were documented. Survival rates were 87%, 80%, and 55%, and event-free survival rates were 80%, 65%, and 39% at 2, 5, and 10 years after surgery, respectively. The late survival rate was unfavorably influenced by the presence of moderately or severely impaired left ventricular function and double-vessel coronary disease; the rate was enhanced for patients in age group from 50 to 59 years old and was not influenced by the method of myocardial protection. The event-free survival rate decreased with the presence of moderately or severely impaired left ventricular function and was enhanced for patients with New York Heart Association class I or II symptoms before surgery. Patients with bioprostheses who did not receive anticoagulants had higher survival'and event-free survival rates than did either patients with bioprostheses who received anticoagulants or patients with mechanical valves, whether they received anticoagulants or not. Circulation 68, No. 6, 1149No. 6, -1162No. 6, , 1983 BOTH aortic valve disease and coronary atherosclerosis have been shown to compromise survival.1' 2 The parallel development of coronary arteriography and cardiac surgery has meant that the natural history of patients with a combination of aortic valve and coronary disease will not be known. Moreover, the existence of combined pathologic causes creates a large number of patient-related variables. Operations for replacement of the aortic valve combined with coronary revascularization are time consuming and stress our strategies for protecting the myocardium and preventing perioperative end-organ injury. The operative result imposes further variables that may potentially influence morbidity and mortality.
The complexity of the patient-and operation-related variables presents multiple issues regarding management, including the indications for revascularization, optimal techniques of intraoperative management, selection of aortic valve prostheses, anticoagulant prophylaxis, and the long-term efficacy of surgery. Some insight can be gained by determining the relative influence of patientand operation-related variables for patients in a surgical series from a single institution, provided the sample is large enough and the length of follow-up is sufficient. To identify determinants of early and late morbidity and mortality, data from the first 500 patients who had undergone primary surgery for aortic valve replacement combined with coronary bypass grafting from 1967 to 1981 were reviewed.
Methods and definitions
Patients. With the aid of a computerized cardiovascular information registry, the first 500 patients who had undergone aortic valve replacement combined with simultaneous coronary bypass grafting were identified. Excluded were those who had Vol. 68, No. 6, December 1983 NO 6 1983 undergone cardiac reoperation, simultaneous cardiac or noncardiac operations other than aortic valve replacement and bypass grafting, or bypass grafting for an indication other than coronary atherosclerosis. Preoperative, operative, and postoperative hospital data were obtained from hospital records, then were computerized for statistical analyses. Preoperative data (tables 1 and . Historical data, including the presence and duration of preoperative symptoms and preoperative New York Heart Association (NYHA) functional class,3 were recorded by The Cleveland Clinic Foundation physician examining the patient before surgery. Preoperative radiographs were available for all patients. Cardiac enlargement was defined as a cardiothoracic ratio o1 greater than 50% in the posteroanterior projection. Preoperative electrocardiograms were available for all but eight patients. Included in the data base were preoperative transmural myocardial infarction (Q or absent Q waves), atrioventricular conduction defect (first-, second-, or third-degree atrioventricular block and complete or incomplete bundle branch block), and atrial fibrillation. All patients underwent preoperative left heart catheterization, left ventriculography, and coronary arteriography. Of the preoperative catheterizations, 314 were performed at The Cleveland Clinic Foundation, and all studies were reviewed by a Cleveland Clinic Foundation cardiologist before surgery. Categorization of the extent of preoperative coronary atherosclerosis into single-, double-, or triple-vessel disease was based on a 70% or greater estimated narrowing of lumen diameter of the left anterior descending, circumflex, or right coronary artery representing a significant stenosis. A 50% or greater reduction of the internal diameter of the left main coronary artery was considered to be a severe stenosis of that artery and doublevessel disease. Stenoses of branch vessels supplying more than 50% of the distribution of a major vessel were classed as stenoses of that major vessel. For patients with left-dominant coronary systems, the number of myocardial segments in jeopardy (of six total segments) determined classification into doublevessel disease (three or four segments jeopardized) or triplevessel disease (five or six segments jeopardized). Left 1150 angiogram of the left ventricle taken in the 30 degree right anterior oblique view. The ventricle was divided into six segments and wall motion was assessed. On the basis of segmental impairment, patients were grouped into categories of normal (no impairment or impairment of a fraction of a segment), minor impairment (hypokinesis or akinesis limited to one segment), moderate impairment (hypokinesis or akinesis of at least two segments), or severe impairment (hypokinesis or akinesis of three or more segments). In addition, the degree of diffuse left ventricular contraction abnormality was assessed subjectively and was classed into categories of normal, mild impairment, moderate impairment, and severe impairment. Patients were placed in a left ventricular functional class (determined by ventriculography) according to the most severely impaired category assigned by either segmental analysis or overall subjective analysis. Preoperative left ventricular end-diastolic pressure was recorded for 415 patients. Aortic valve lesions were classified as stenosis, insufficiency, or mixed lesions. The diagnosis of aortic stenosis was based on the measurement of peak systolic aortic valve gradient in 242 patients and on angiographic and clinical criteria in 52. Patients with mixed lesions combined at least 1/4 + angiographic aortic insufficiency4 with either an aortic systolic gradient of 20 mm hg (87 patients) or the angiographic appearance of decreased valve motion and stenosis (30 patients). Eighty-nine patients had aortic insufficiency. Valve areas were not calculated because of inconsistent hemodynamic measurements.
During the period under review, coronary arteriography was routinely performed before aortic valve replacement. Bypass grafting was undertaken if significant stenoses were present angiographically and when, in the surgeon's opinion, revascularization was technically possible.
Operative data (table 3) . Complete revascularization was defined as bypass of all major vessels significantly (>70%) obstructed. Obstructions of branch vessels that could not be bypassed designated the patient as having "incomplete revascularization" when those vessels supplied more than 50% of the distribution of the major vessel. Nondominant right coronary artery obstructions and obstructions of vessels perfusing akinetic segments (confirmed transmural scar) were excluded in establishing the completeness of revascularization. The number of distal anastomoses was used to designate the number of grafts. A total of 834 grafts were performed, 370 to the anterior descending-diagonal system, 231 to the circumflex, and 233 to the right coronary artery (1.7 grafts per patient).
Valve selection was based primarily on surgeon preference. Only mechanical prostheses were implanted before 1975, and some surgeons have used mechanical prostheses by preference throughout the period of the study. Since 1975, some surgeons have used bioprostheses by preference, with the presence of a small aortic root considered as a relative indication for placement of a mechanical valve.
Strategies for intraoperative myocardial protection included normothermic, intermittent, anoxic arrest (227 patients, 45%), anoxic arrest combined with systemic hypothermia (33 patients, 7%), continuous coronary perfusion with oxygenated blood (three patients, 1%), and use of cold potassium-based asanguineous cardioplegia (237 patients, 47%). Before 1976, intermittent anoxic arrest was used for all of our patients except the three with coronary perfusion.
For analyses of the influence of the date of operation, the group was divided into two surgical periods, 1967 to 1977 and 1978 to 1981. These years were selected for three reasons: first, this division approximately bisects the study group; second, since 1978 the surgeons involved have remained constant; and third, 1978 correlated with a decrease in in-hospital mortality that has since been maintained.
Postoperative hospital data. In-hospital mortality, or early death, was defined as death during hospitalization for surgery regardless of duration. Death after discharage from hospitalization for surgery was considered late death. Primary causes of inhospital deaths were established by review of hospital records and autopsy data (17 patients) .
Postoperative electrocardiograms for all survivors of surgery were reviewed by the attending cardiologist. The postoperative appearance of new Q waves or loss of R waves was entered into the data base; ST or T wave changes were not considered. A postoperative SGOT value for one of the first two postoperative days was available for all patients. When multiple values were available the highest was recorded. Data on other enzyme determinations were not used because of inconsistent availability throughout the study period.
Follow-up. Direct telephone contact with all survivors was established by trained personnel except for four foreign patients who were contacted by telegrams and letters. When interim events or hospitalizations had occurred, the patient's personal physician and hospital were contacted for further documentation. For patients dying after hospital discharge, data regarding premorbid symptoms, clinical events, anticoagulation status, and cause of death were obtained from surviving family members, physician or hospital records, and autopsy records (20 patients Hospitalization for a clinical syndrome based on acute arterial occlusion excluding neurologic events. Anticoagulation status. Patients were separated into groups receiving or not receiving anticoagulants based on whether or not they were taking warfarin at follow-up. Patients who had not been taking warfarin for at least 2 weeks before death or occurrence of a morbid event were classed as not receiving anticoagulants. For many patients with bioprostheses and some with mechanical prostheses, warfarin had been discontinued on a permanent basis because of physician preference. For others warfarin was discontinued because of the need for a surgical procedure or the occurrence of complications of anticoagulation. Patients with bioprostheses routinely received warfarin for 6 weeks after surgery. If warfarin was then discontinued they were classed as not receiving anticoagulants. Adequacy of anticoagulation for patients receiving anticoagulants was not assessed, and platelet-inhibiting drugs were not considered.
Statistical methods. The univariate influences of variables concerning end points unrelated to time were tested by chisquare analyses or Fisher's exact test. Stepwise multiple logistic regression analysis was then used to further test significant variables in a multivariate situation.5 Relationships of variables to death or time to occurrence of a late cardiac event were examined by univariate analysis with life table methods and the generalized Wilcoxon test to examine equality of actuarial curves.6 Multivariate analyses concerning time-related events were accomplished with the Cox proportional hazard regression model.7
Results

Early results
In-hospital mortality. Twenty-nine (5.8%) in-hospital deaths occurred. Nine patients died during surgery. Thirteen died after surgery with new myocardial infarction documented either by electrocardiography (new Q waves or loss of R waves) or by autopsy, and two patients died of low cardiac output but without new infarction. Primary causes of death in other patients were stroke (two patients), endocarditis (one patient), and renal failure (one patient). One patient died from multiple factors without a discernible primary cause. 1152 Cardiac morbidity. Of patients surviving surgery (491 patients), 32 had new Q waves documented electrocardiographically. For all 32 the postoperative SGOT level was abnormal (>50 U), and 10 (31%) of these patients died in the hospital. In patients without new Q waves, enzyme elevation alone was not associated with increased in-hospital mortality. If the SGOT level was B 140 U there was a trend toward increased mortality, i.e., four of 86 patients (5%) with SGOT levels Ba140 and five of 372 patients (1%) with SGOT levels <140 died (p -NS). Lesser elevations of SGOT levels (50 to 140 U) were not associated with increased in-hospital mortality.
The type of myocardial protection used had an influence on cardiac morbidity. Twenty-one of 254 patients (8%) operated on by use of anoxic arrest had new Q waves compared with 10 of 234 patients (4%) in the group receiving cardioplegia (p -.07). The mean postoperative SGOT for patients operated on with anoxic arrest was 190 U; for those receiving cardioplegia, it was 88 U. An increase in total aortic occlusion time was related to an increase in postoperative SGOT for patients operated on by use of anoxic arrest (p .003) but not for those who received cardioplegia. Noncardiac morbidity. Ninety-five patients (19%) experienced noncardiac morbidity. The number of patients and percent of the group with each complication were: bleeding (postoperative hemorrhage requiring reoperation), 69 (14%); wound complications (extending hospitalization), nine (2%); stroke (new focal postoperative neurologic deficit, transient or permanent), 15 (3%); respiratory failure (requiring mechanical ventilation beyond 72 hr), 18 (4%); sepsis (documented bacteremia or positive sputum cultures associated with febrile illness and infiltrate on chest radiograph), 10 (2%); and renal failure (blood urea nitrogen > 100), nine (2%). Univariate testing of the likelihood of mortality once each complication had occurred showed that all were significantly associated with eventual inhospital mortality (all p values <.05). When patients who experienced cardiac morbidity (new Q waves) were excluded from analysis, there still was a significant association of noncardiac morbidity with in-hospital mortality (p -.002). Furthermore, for the subset of patients with new postoperative Q waves (32 patients), of the 13 patients who also had noncardiac morbidity, eight died (62%) compared with two (11%) of the 19 patients without noncardiac morbidity (p = .002). Noncardiac morbidity was not related to either myocardial protection or period of surgery (1967-1977 or 1978-1981) .
Preoperative variables. Tables 1 and 2 detail the distri-CIRCULATION bution of the study group according to preoperative clinical and catheterization variables and also show results of the univariate analyses concerning the influence of these variables on in-hospital mortality. Age at surgery (mean 61.6 years, range 34-84) was examined according to decade of life and as a continuous variable. In addition, comparison of the mean age of survivors (61.5 ± 8.2 years) and those who did not survive (64.0 ± 7.8 years) showed no significant difference.
Of the study group, 82% had experienced preoperative angina. Angina was present in 78% of those with single-vessel disease, in 83% with double-vessel disease, and in 90% with triple-vessel disease (p = .02). Fewer patients with aortic insufficiency had angina (73%) than did those with mixed lesions (85%) or stenoses (84%) (p = .04).
For patients 70 years old or older there was a trend toward an increased prevalence of triple-vessel disease (32%) (p = .06). The extent of coronary disease was not related to left ventricular function.
Gender was associated with increased age (p = .003) because 27% of the women were 70 years old or older compared with 13% of the men. However, there was no difference between men and women in type of lesion, left ventricular function, left main stenosis, extent of coronary disease, cardiac enlargement, or NYHA functional class.
In addition to the examination of the maximum duration of any symptom according to the intervals listed in table 1, the durations of individual symptoms before surgery were divided into 6 month intervals and were tested for their influence on risk at surgery. None of these groups had a significant influence on in-hospital mortality.
When the effect of angiographically defined left ventricular function and left ventricular end-diastolic pressure were tested, extreme categories were tested against each other as well as against the remainder of the group. No subgroups were associated with increased risk at surgery. Only seven patients had atrial fibrillation before surgery, which is not enough for meaningful analysis. Univariate examination of preoperative variables showed risk at surgery to be increased for women, patients with radiographically defined cardiac enlargement, and for those with aortic insufficiency (all p values -.05).
Operative variables. Table 3 lists the distribution of the study group according to operative variables and the univariate influence of these variables on in-hospital mortality.
Vol. 68, No. 6, December 1983 Comparison of the group that received normothermic anoxic arrest with the group that received hypothermic anoxic arrest showed equivalent in-hospital mortality. For further analyses, these two groups were combined into a single group. Patients with coronary perfusion (three patients, no mortality) undergoing surgery were excluded from analysis of type of myocardial protection but were included in other analyses.
The influence of aortic occlusion time (data not in table 3) was examined separately for the group that received anoxic arrest and the group that received cardioplegia. All periods of occlusion for each patient were added and the resulting total cross-clamp times were grouped by 20 min intervals and by the method of myocardial protection. Occlusion time with cardioplegia tended to be longer than with anoxia (mean 68 + 16 vs 50 ± 15 min), but was less than 60 min for 85% of patients in whom anoxic arrest was used and less than 100 min for 85% in whom cardioplegia was used. Cross-clamp time was not related to mortality for either method of myocardial protection. The single longest period of aortic occlusion for each patient was examined in similar fashion, and again no influence on mortality was demonstrated.
The types of aortic valve prostheses are shown in table 4. Analyses were carried out with valves grouped into the major categories of mechanical prostheses and bioprostheses. Further subgrouping of the mechanical prostheses, comparisons of ball valves vs disc valves, and comparisons of individual makes of valves with each other identified no highor low-risk subgroup.
Univariate analysis showed that the period of surgery and method of myocardial protection had an influence on operative mortality (both p < .10).
Period of surgery. The distribution of patients according to many preoperative and operative variables differed between the two periods of surgery. In the 1978 to 1981 period, patients more commonly were women (p = .04), were older (p -.0001), had multivessel coronary disease (p = .06), had mixed valve lesions (p = .03), and had radiographically defined cardiac enlargement less frequently (p = .01). Operations in the more recent period were associated with use of cardioplegia (p -.0001), complete revascularization (p = .006), and placement of bioprostheses (p -.0001). For patients who underwent surgery before 1978, 66% received one graft, 26% received two grafts, and 8% received three grafts. In the 1978 to 1981 period, 36% had one graft, 43% had two grafts, 16% had three grafts, and 5% had more than three grafts. In this multivariate analysis (table 5), female sex and aortic insufficiency increased operative mortality, and use of cardioplegia decreased operative mortality.
An increase in age marginally increased risk.
Late results
Late survival. Of the 471 survivors of hospitalization, 96 subsequently died. No late survivors were lost to follow-up (mean follow-up interval 41 months, range 1 to 135). Survival rates excluding operative mortality (figure 1) were 87%, 80%, and 55%, at 2, 5, and 10 years after surgery, respectively. Primary causes of death are listed in table 6. Seventy-six deaths were clearly cardiac; 20 were judged to be noncardiac. Postoperative interval did not appear to alter the proportion of cardiac vs noncardiac deaths. However, cardiac PERCENT .02), complete revascularization (p = .06), and use of a bioprothesis (p = .007).
For (B 140 U, p = .14) predicted a decrease in long-term survival rate. However, late survival figures for patients experiencing noncardiac morbidity after surgery were slightly lower than the figures for the rest of the group (p = .04). The long-term management variable we examined was anticoagulation with warfarin. Because the implications of anticoagulation are different for patients with mechanical prostheses and bioprostheses, these variables were examined by dividing the study group into four subgroups based on the type of prosthesis and anticoagulation status. These groups were patients with mechanical prostheses who received anticoagulants (213 patients), those with mechanical prostheses who did not receive anticoagulants (40 patients), those with bioprostheses who received anticoagulants (77 patients), and those with bioprostheses who did not receive anticoagulants (141 patients). The survival rate was significantly different for the prosthesis-anticoagulation groups (figure 4). Patients with bioprostheses who did not receive anticoagulants had the best survival rate, whereas those with mechanical prostheses who did not receive anticoagulants had the worst (p < .0001). Long-term survival rates for all patients who have bioprostheses compared with all those who have mechanical prostheses, regardless of anticoagulation status, is shown in figure 5 . Separation of patients with mechanical prostheses into ball-valve (Starr-Edwards, Cutter-Smeloff) and disc-valve (Bjork-Shiley, Lillehei-Kaster) groups showed that patients with ball valves had 2 months was 76% for patients with bioprostheses who received anticoagulants and 90% for those with bioprostheses who did not receive anticoagulants. The survival rate at 48 months was 82% for those with mechanical prostheses who received anticoagulants and 59% for those with mechanical prostheses who did not receive anticoagulants.
survival rates of 86% and 70%, respectively, compared with 81% and 70% for those with disc valves (p = NS). patient-related variables was examined. Prosthesis type and gender were not associated, although women with either mechanical valves or bioprostheses were more likely to receive warfarin than were men (p .007). Patients with mechanical valves who did not receive anticoagulants were more likely to have radiographically defined cardiac enlargement, whereas those with bioprostheses who did not receive warfarin were less likely to have enlargement (p = .05). Valveanticoagulation groups were not significantly different with respect to left ventricular function, NYHA functional class, valve lesion, extent of coronary disease, and age. Survival rate and period of surgery. To test the influence of the period of surgery, further examinations were carried out, with valve-anticoagulation status receiving particular attention. Survival curves for patients operated on in the 1978 to 1981 period and grouped according to valve-anticoagulation status demonstrated results similar to those obtained when all patients were examined. Patients with bioprostheses who did not receive anticoagulants had better survival rates (p = .0001) than did patients in other subgroups. Furthermore, when patients with mechanical prostheses who received anticoagulants were grouped according to the period during which they underwent surgery, survival rates for the first 36 months after surgery (p = .97) for patients operated on in the two periods were equivalent. 8) . Of seven cardiac reoperations, two were for myocardial revascularization and five were for valve-related complications. For one patient a combination of vein graft atherosclerosis and progression of atherosclerosis in the native coronary circulation led to reoperation for revascularization 94 months after surgery. A second patient died at reoperation for graft failure 6 months after surgery. Three patients were operated on 1, 3, and 22 months after the original operation for perivalvular leaks without infection. One death at surgery occurred. One patient underwent reoperation for a perivalvular leak because of endocarditis 5 months after surgery. Also, porcine valve calcification led to reoperation at 35 months for one patient. Actuarial event-free survival curves were constructed considering death from any cause or the occurrence of a major late complication as an end point. Eventfree survival rates for the 471 survivors of hospitalization (figure 1) were 80%, 65%, and 39% at 2, 5, and 10 years after surgery, respectively.
Univariate analysis of event-free survival rates. The influences of preoperative, operative, and postoperative variables on event-free survival rates were tested by univariate analysis in similar fashion to the late survival rate analyses.. Influential trends modifying event-free survival rates were shown for preoperative NYHA functional class (class I and II vs III vs IV) (p .08), preoperative left ventricular function (normal and mild vs moderate and severe) (p = .05), cardiac enlargement (p -.004), complete revascularization (p = .08), myocardial protection (p =.04), and prosthesis-anticoagulation group (p = .0003).
Multivariate analysis ofevent-free survival rates. Age category was included in the multivariate analysis along with the variables listed above that were influential in the univariate analysis. Table 7 shows results of that model and indicates that preoperative NYHA functional class significantly altered event-free survival rate although it had no effect on survival rate alone. Preoperative left ventricular functional class remained influential as did the variable for prosthesis-anticoagulation group. The presence of a bioprosthesis in a patient who did not receive anticoagulants was associated with a risk of a late complication or death that was less than half that of the rest of the group.
Cardiac survival and cardiac event-free survival rates.
When deaths from causes judged to be noncardiac were excluded from survival and event-free survival rate analyses, there was no change in the relative importance of the variables influencing survival and event-free survival rates.
Postoperative status. The breakdown for postoperative NYHA functional class for the 375 late survivors was I, 291 (78%); II, 76 (20%); III, five (1%); and IV, three (1%). Of the 84 patients with symptoms, 49 reported angina and 54 reported dyspnea. The number of functional classes improved over preoperative status were three for 33 patients (9%); two for 114 (30%); one for 176 (47%); and zero for 48 (13%); four patients (1 %) were worse by one class. The proportion of survivors without symptoms decreased with increasing follow-up interval, and of 100 patients followed for more than 5 years, 63% were asymptomatic. 1158
Postoperative graft angiography. Fifty-five patients underwent postoperative angiography 1 to 109 months (mean interval 28) after surgery. Of 78 grafts evaluated, 65 (83%) were patent including 26 of 31 (84%) left anterior descending artery grafts, 16 of 21 (76%) circumflex artery grafts, and 23 of 26 (88%) right coronary artery grafts.
Discussion
In these 14 years under study, patient characteristics associated with higher risk were seen more frequently from 1978 to 1981. The increases in the prevalence of women, older patients, and multivessel coronary atherosclerosis in patients undergoing aortic valve replacement and bypass grafting correspond with changes in the population of patients receiving isolated coronary revascularization.8 As the patient population changed, so did management strategy. The most striking alteration was the use of cold cardioplegia for intraoperative myocardial protection. The number of grafts per operation increased in more recent years because of an increasing prevalence of both multivessel coronary disease and complete revascularization. The use of bioprostheses, initiated in 1975, has increased, but through 1981 these still did not constitute more than 72% of prostheses, which made it possible to evaluate mechanical prostheses in both surgical periods. Irrespective of clinical characteristics associated with higher risk, results of surgery in the recent experience improved. Relative to data from the early 1970s,216 others have also reported improved results, including operative mortalities of 3.6%14 and 5.0%,'5 which are no different from those for patients undergoing isolated aortic valve replacement. 14, 16 We found the patient-related indicators of operative mortality to be gender, aortic valve lesion, and age.
Gender was the strongest variable influencing mortality: women were at greater risk than men. Similar findings have been described for patients undergoing isolated coronary revascularization both by the Coronary Artery Surgery Study and by our own studies. 17 18 Why women are at greater risk is not clear. There were no significant differences between men and women regarding other patient-related variables such as valve lesion, extent of coronary disease, and left ventricular function. Although the women were older, age was less influential than gender in the multivariate setting. Technical aspects need consideration. Women tend toward a smaller body surface area, smaller coronary arteries, and smaller aortic roots, which perhaps presents more difficult technical problems intraoperatively. Indeed, for patients undergoing isolated coronary CIRCULATION revascularization, body surface area may be a stronger indicator of risk than gender. 17, 18 We did not examine body surface area. However, review of the operative records of the 11 women who died perioperatively showed that in only four were technical problems encountered that conceivably could have affected the outcome. Gender would remain a significant influence even with exclusion of these four deaths.
Aortic regurgitation increased in-hospital mortality. The influence of aortic insufficiency exceeded those of angiographically defined left ventricular function, cardiothoracic ratio, left ventricular end-diastolic pressure, and symptoms of left ventricular failure. Furthermore, specific examination of patients with aortic insufficiency who also had a high left ventricular enddiastolic pressure or severe left ventricular impairment determined angiographically showed that these subsets of patients had no increase in risk over other patients with aortic insufficiency. These findings imply that when combined with coronary artery disease, the adverse effect of aortic regurgitation is mediated by more than just a correlation with abnormal left ventricular function. The intraoperative problems aortic regurgitation can cause when an intermittent cross-clamping strategy is used for myocardial protection may have been influential, since use of cardioplegia has diminished the adverse effect of aortic insufficiency. An elevated in-hospital risk associated with aortic insufficiency has been identified by Copeland et al.'9 for patients undergoing isolated aortic valve replacement.
As age increased, mortality increased. The influence of age was not clear when mean ages of survivors and patients who did not survive were compared. However, examination of age as a continuous variable did define its influence on risk. Age has also been shown to increase operative risk for patients undergoing isolated coronary revascularization20 and isolated aortic valve replacement.2'
The analysis of left ventricular function and its influence on both early and late survival rates are complex problems in regard to patients with both aortic valve and coronary disease. Segmental dysfunction secondary to myocardial infarction will not be improved by surgery and may theoretically have a more profound effect on risk than the generalized impairment of left ventricular function caused by aortic stenosis. However, neither segmental nor global left ventricular dysfunction were important risk factors. Previous studies of patients undergoing isolated revascularization have cited ejection fraction,22 impaired left ventricular function (determined by angiography), increased left ventricular end-diastolic pressure, and symptoms of con-Vol. 68, No. 6, December 1983 gestive heart failure as increasing risk'7; also, ejection fraction has been identified as increasing the risk of having to undergo aortic valve replacement.23 Ejection fractions were not calculated for the majority of our patients. However, of the variables available, no index of left ventricular function, either invasive or noninvasive, had predictive value regarding in-hospital risk.
The use of cold potassium cardioplegia for myocardial protection decreased in-hospital mortality. Despite extensive experimental data documenting the effectiveness of cardioplegia to protect myocardial function and the distinct clinical impression of many surgeons about its efficacy, clinical data demonstrating a decrease in operative mortality for large patient subgroups associated with the use of cardioplegia have not been extensive. In our experience, operative mortality for patients with isolated coronary revascularization8 and for those undergoing reoperative revasculariza-tion24 has shown a downward trend concomitant with the use of cardioplegia, but not a statistically significant decrease. However, for those subsets of patients, a beneficial influence of cardioplegia on mortality may have been masked by a changing patient population, and cardioplegia has decreased the incidence of perioperative myocardial infarction significantly. The decrease in operative mortality associated with the use of cardioplegia in this study is a clear indication of its effectiveness. Improved myocardial protection has diminished the influence of patient-related variables except for gender. For men, the current 1% operative risk has made other factors irrelevant.
No variable relative to the severity of preoperative coronary artery disease increased in-hospital risk for patients; numbers of grafts performed or complete revascularization also did not increase risk.
In-hospital mortality was highly dependent on cardiac morbidity. All intraoperative deaths were caused primarily by myocardial failure. For patients surviving the operation, myocardial infarction with new Q waves predicted an in-hospital mortality of 31%. Elevation of postoperative SGOT levels without new Q waves was less of an indicator, and not until the level reached 140 U/100 ml was there a trend toward increased mortality. Similar observations of perioperative myocardial injury and in-hospital mortality were made by Richardson et al.25
Increasing aortic cross-clamp time was not associated with operative mortality or the appearance of new postoperative Q waves when either cardioplegia or anoxic arrest was used. This observation is at variance with data on aortic occlusion time and mortality for patients undergoing valve reoperations reported by 1159 Wideman et al. 26 In our series, the range of occlusion times may not have placed significant numbers of patients above the safe limits for these methods of myocardial protection. However, postoperative SGOT levels increased with increasing aortic cross-clamp time for patients with ischemic arrest but not for patients in whom cardioplegia was used.
Although most primary causes of death appeared to be cardiac, noncardiac morbidity was also associated with operative mortality. When a patient would have a complex postoperative course, it would be more difficult to distinguish between cause and effect, the patient's postoperative hemodynamic derangement would be more serious, and it would be more likely that noncardiac morbidity would occur. Reexploration for postoperative bleeding, usually not related to cardiac dysfunction, tripled the eventual mortality. When the subset of patients suffering perioperative myocardial infarction was examined, the occurrence of noncardiac morbidity greatly increased mortality. Noncardiac morbidity was not decreased by either cardioplegia or surgical period.
Although the natural history of patients with aortic valve disease and significant coronary atherosclerosis managed nonsurgically is unknown, some data exist on the survival rate of patients with coronary artery and aortic valve disease undergoing only aortic valve re- Most studies of patients undergoing isolated aortic valve replacement have designated patient-related variables as the most significant determinants of late risk.
Preoperative cardiothoracic ratio,'9' 28. 29 left ventricular end-diastolic pressure,30 ejection fraction,23 symptoms of congestive heart failure,'9 and NYHA functional class'9 28 are all indexes related in part to preoperative left ventricular function and have been identified by one study or another as indicators of late survival. The type of valve lesion has been implicated as an indicator, with aortic regurgitation adversely influencing survival rate; Copeland et al. '9 also identified age, previous myocardial infarction, and the presence of coronary artery disease as other significant patientrelated variables.
We found that three patient-related variables (age, preoperative left ventricular functional class determined by angiography, and the extent of coronary disease) significantly influence late survival rate. Patients in the 50 to 59 year age group had a better survival rate than both older and younger patients. Preoperative left ventricular function as determined by angiography influenced late survival rate, but not dramatically. Even for patients with moderate or severe impairment of left ventricular function, the 5 year survival rate was 69%, and examination of the severely impaired group alone showed no increase in risk. The number of coronary vessels significantly stenotic is an indicator of late survival for patients undergoing surgery8-1 ' and those not undergoing surgery2 who have isolated coronary artery disease. In this study, patients with double-vessel disease appeared to have an impaired survival rate relative to those with singleor triple-vessel disease. The reason for the adverse effect of double-vessel disease is not clear.
Valve lesion, gender, and the use of cardioplegia, all influencing operative risk, had no effect on late survival rate. Concern that patients receiving suboptimal intraoperative myocardial protection might survive surgery but succumb to late ischemic cardiomy-opathy32 could not be supported. Use of cardioplegia has a clear benefit, but its influence is relegated to a diminished in-hospital risk.
The most significant determinants of late survival were type of prosthesis and status of anticoagulation. Oyer et al. 33 believed bioprostheses enhanced survival rate relative to ball-valve prostheses, although the patients with the two types of valves underwent surgery in surgical periods that did not overlap. No other stud-CIRCULATION 1160 ies have indicated an influence of prosthesis type on survival rate, either when bioprostheses and mechanical prostheses were compared or when ball valves were compared with disc valves.3" We could demonstrate no difference in survival rate when ball valves were compared with disc valves.
Patients with bioprostheses had a better survival rate than did those with mechanical prostheses. However, anticoagulation with warfarin heavily influenced the survival rate of patients with mechanical valves. We analyzed the influence of prosthesis and anticoagulation jointly so the survival rate of the subgroup of patients not receiving anticoagulants would not unfavorably bias the judgment of mechanical prostheses in general. Not only was lack of anticoagulation detrimental to patients with mechanical valves, but the advantage for bioprostheses was based on an extremely favorable survival rate for patients with bioprostheses who did not receive anticoagulants. Patients with mechanical prostheses and those with bioprostheses who received anticoagulants had similar survival rates.
Review of the causes of late mortality stratified according to the prosthesis-anticoagulation group does not reveal precisely why patients with bioprostheses who did not receive anticoagulants had a better survival rate. Only one death could be attributed to complications of anticoagulation in patients receiving warfarin. The large category of sudden death probably includes many pathologic causes. Patients with clinical histories compatible with the classification sudden death were found to be victims of stroke, myocardial infarction, and catastrophic valve failure at autopsy. Death is a clear end point accurately definable in a follow-up study; cause of death is less so. To avoid editorializing by methodology, all deaths were included in survival analyses.
To designate prosthesis type as a significant influence on late risk, it is necessary to establish that other variables, unevenly distributed among valve-anticoagulation groups, are not the factors responsible for survival rate differences. The multivariate nature of the survival analyses establish that valve-anticoagulation status was more influential than the other variables included in the statistical model. Furthermore, specific analyses of valve-anticoagulation groups in regard to patient-related variables demonstrated only small differences. Although period of surgery was associated with a changing pattern of prosthesis selection, enough mechanical valves have been placed recently to allow evaluation of survival rates in both surgical periods. We found no difference in late survival or event-free survival rates when the patients with mechanical prostheses who received anticoagulants were compared from the two periods of surgery. Macmanus et al. 35 also found no difference in late survival rate according to year of operation, but they did believe that the incidence of late complication (thromboembolism) had diminished recently.
Valve-anticoagulation status had a major influence on late event-free survival rate, which was best for patients with bioprostheses who were not receiving anticoagulants. When morbid events were considered along with mortality, the relative influence of the presence of a mechanical prosthesis in patients not receiving anticoagulants was diminished, probably because events that occur for this subgroup tend to be fatal. The influence of preoperative left ventricular function determined angiographically was stronger on event-free survival rate than on survival rate alone. Preoperative NYHA functional class, which had no effect on survival rate alone, did have a significant influence on the event-free survival rate.
Few patients in this study with bioprostheses have been followed up beyond 54 months, and conclusions about the relative efficacy of mechanical valves and bioprostheses are limited to that time frame. At this point after surgery, failure of bioprostheses has not yet become a significant factor. It can no longer be argued that revascularization concomitant with aortic valve replacement might increase operative mortality. The low operative risk and favorable long-term survival rate of this study group combined with the low prevalence of angina among late survivors has encouraged us to continue a policy of myocardial revascularization for patients with significant coronary artery disease who need aortic valve replacement. Furthermore, no combination of patientrelated variables currently predicts a dismal long-term result. Of patients receiving bioprostheses, 18 were 70 years old or older and also had moderate or severe left ventricular impairment. The survival rate of that "high-risk" group was still 64% at 4 years after surgery. Bioprostheses offer a survival advantage for at least 41/2years after aortic valve replacement and myocardial revascularization.
